Ruxolitinib: a targeted treatment option for patients with polycythemia vera [0.03%]
鲁索利替尼：治疗真性红细胞增多症患者的一种靶向治疗选择
Kris Vaddi,Srdan Verstovsek,Jean-Jacques Kiladjian
Kris Vaddi
Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by erythrocytosis and the presence of Janus kinase (JAK) 2V617F or similar mutations. This review summarizes the pathophysiology of PV, the challenges associated ...
Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies [0.03%]
复发/难治性霍奇金淋巴瘤发病机制及治疗的进展：靶向治疗和移植策略为重点
Theodoros Karantanos,Ioannis Politikos,Vassiliki A Boussiotis
Theodoros Karantanos
Hodgkin's lymphoma (HL) is highly curable with first-line therapy. However, a minority of patients present with refractory disease or experience relapse after completion of frontline treatment. These patients are treated with salvage chemot...
Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas [0.03%]
伊匹拉利西姆治疗惰性B细胞恶性肿瘤：慢性淋巴细胞性白血病和小淋巴细胞性或滤泡性淋巴瘤
Yazan F Madanat,Mitchell R Smith,Alexandru Almasan et al.
Yazan F Madanat et al.
Chronic lymphocytic leukemia, small lymphocytic lymphoma, and follicular lymphoma are indolent B-cell lymphoproliferative disorders that mainly affect an older population. Although the majority of patients in need of treatment derive signif...
Profile of elotuzumab and its potential in the treatment of multiple myeloma [0.03%]
elotuzumab的特性及其在多发性骨髓瘤治疗中的应用前景
Yi-Chang Liu,Susann Szmania,Frits van Rhee
Yi-Chang Liu
Although the introduction of novel drugs has improved outcome significantly in multiple myeloma (MM), many patients still eventually relapse. Monoclonal antibodies (mAbs) targeting MM-related antigens can complement currently available ther...
Treatment Strategies for Patients with Diffuse Large B-Cell Lymphoma: Past, Present, and Future [0.03%]
弥漫性大B细胞淋巴瘤的治疗策略：过去、现在和未来
Rajni Sinha,Loretta Nastoupil,Christopher R Flowers
Rajni Sinha
Diffuse large B-cell lymphoma (DLBCL) is the most commonly occurring lymphoma in the Western world. DLBCL is a clinically, biologically, and pathologically heterogeneous entity with biologically distinct subtypes that have different expecte...